Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.

Objective This study aims to comparatively analyze the therapeutic efficacy upon multiple medication plans over Lopinavir/Ritonavir (LPV/r), Arbidol (ARB) and Methylprednisolone on patients with Coronavirus Disease 2019 (COVID-19). Methods Totally 75 COVID-19 patients admitted to The First Affiliated Hospital, Zhejiang University School of Medicine from January 22, 2020 to February 29, 2020 were recruited and grouped based on whether or not LPV/r and ARB were jointly used and whether or not Methylprednisolone was used. Indexes including body temperature, time for nucleic acid negative conversion, hospital stays and laboratory indexes were examined and compared. Results For all patients, there were no significant differences in the change of body temperature, the time for negative conversion and hospital stays whether LPV/r and ARB were jointly used or not. While for severe and critically severe patients, Methylprednisolone noticeably reduced the time for negative conversion. Meanwhile, the clinical efficacy was superior on patients receiving Methylprednisolone within 3 days upon admission, and the duration of hospital stays was much shorter when Methylprednisolone was given at a total dose of 0-400 mg than a higher dose of >400 mg if all patients received a similar dose per day. Nonetheless, no significant changes across hepatic, renal and myocardial function indexes were observed. Conclusion LPV/r combined with ARB produced no noticeably better effect on COVID-19 patients relative to the single agent treatment. Additionally, Methylprednisolone was efficient in severe and critically severe cases, and superior efficacy could be realized upon its early, appropriate and short-term application. This article is protected by copyright. All rights reserved.